Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
In the latest session, Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) closed at $1.23 down -2.38% from its previous closing price of $1.26. In other words, the price has decreased by -$2.38 from its previous closing price. On the day, 0.77 million shares were traded.
Ratios:
For a deeper understanding of Zentalis Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.32 and its Current Ratio is at 7.32. In the meantime, Its Debt-to-Equity ratio is 0.13 whereas as Long-Term Debt/Eq ratio is at 0.12.
On June 20, 2024, UBS Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $28 to $5.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Apr 30 ’25 when Myers Scott Dunseth bought 21,000 shares for $1.40 per share. The transaction valued at 29,373 led to the insider holds 281,192 shares of the business.
Bruns Ingmar bought 20,000 shares of ZNTL for $45,656 on Feb 06 ’25. The Chief Medical Officer now owns 36,629 shares after completing the transaction at $2.28 per share. On Feb 11 ’25, another insider, Cam Gallagher, who serves as the Former Director of the company, bought 687 shares for $2.00 each.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 1.31 while its Price-to-Book (P/B) ratio in mrq is 0.26.
Stock Price History:
Over the past 52 weeks, ZNTL has reached a high of $13.24, while it has fallen to a 52-week low of $1.01. The 50-Day Moving Average of the stock is -20.50%, while the 200-Day Moving Average is calculated to be -54.82%.
Shares Statistics:
A total of 71.28M shares are outstanding, with a floating share count of 54.40M. Insiders hold about 24.69% of the company’s shares, while institutions hold 87.42% stake in the company.
